Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
Top Cited Papers
- 16 August 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (10), 1429-1437
- https://doi.org/10.1093/neuonc/not114
Abstract
To determine the protective effects of memantine on cognitive function in patients receiving whole-brain radiotherapy (WBRT). Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine (20 mg/d), within 3 days of initiating radiotherapy for 24 weeks. Serial standardized tests of cognitive function were performed. Of 554 patients who were accrued, 508 were eligible. Grade 3 or 4 toxicities and study compliance were similar in the 2 arms. There was less decline in delayed recall in the memantine arm at 24 weeks (P = .059), but the difference was not statistically significant, possibly because there were only 149 analyzable patients at 24 weeks, resulting in only 35% statistical power. The memantine arm had significantly longer time to cognitive decline (hazard ratio 0.78, 95% confidence interval 0.62–0.99, P = .01); the probability of cognitive function failure at 24 weeks was 53.8% in the memantine arm and 64.9% in the placebo arm. Superior results were seen in the memantine arm for executive function at 8 (P = .008) and 16 weeks (P = .0041) and for processing speed (P = .0137) and delayed recognition (P = .0149) at 24 weeks. Memantine was well tolerated and had a toxicity profile very similar to placebo. Although there was less decline in the primary endpoint of delayed recall at 24 weeks, this lacked statistical significance possibly due to significant patient loss. Overall, patients treated with memantine had better cognitive function over time; specifically, memantine delayed time to cognitive decline and reduced the rate of decline in memory, executive function, and processing speed in patients receiving WBRT. RTOG 0614, ClinicalTrials.gov number CT00566852.Keywords
This publication has 33 references indexed in Scilit:
- Early measures of cognitive function predict survival in patients with newly diagnosed glioblastomaNeuro-Oncology, 2012
- Primary Analysis of a Phase II Randomized Trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of Different Total Doses and Schedules of Prophylactic Cranial Irradiation on Chronic Neurotoxicity and Quality of Life for Patients With Limited-Disease Small-Cell Lung CancerInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life AnalysisJournal of Clinical Oncology, 2011
- Whole-Brain Radiotherapy in the Management of Brain MetastasisJournal of Clinical Oncology, 2006
- Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2004
- Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular DementiaStroke, 2002
- GlycineB antagonists as potential therapeutic agentsAmino Acids, 1998
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology*Biology*Physics, 1997
- The randomization and stratification of patients to clinical trialsJournal of Chronic Diseases, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958